Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition

PURPOSE: Although KRAS represents the most commonly mutated oncogene, it has long been considered an “undruggable” target. Novel covalent inhibitors selective for the KRAS(G12C) mutation offer the unprecedented opportunity to target KRAS directly. However, prior efforts to target the RAS-MAPK pathwa...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Clin Cancer Res
Hoofdauteurs: Ryan, Meagan B., de la Cruz, Ferran Fece, Phat, Sarah, Myers, David T., Wong, Edmond, Shahzade, Heather A., Hong, Catriona B., Corcoran, Ryan B.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2019
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7124991/
https://ncbi.nlm.nih.gov/pubmed/31776128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3523
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items